The specific p53 mutants used in this study showed that resistance to the chemotherapy drug doxorubicin will likely be resolved by administering it as a co-treatment together with HSP70 inhibitors in breast cancer for future potential application in clinical usage. Here, TP53 is linked to breast carcinoma.